Celebrex (celecoxib) is the first drug to be approved for a hereditary form of colorectal cancer
Celebrex (celecoxib) is the first drug to be approved for a hereditary form of colorectal cancer.
It'll be used to help reduce the number of intestinal polyps in patients with familial adenomatous polyposis (FAP).
Blocking the COX-2 enzyme seems to reduce blood supply to the polyp and therefore inhibit growth.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
 - Quick, practical reference charts and tools
 - Comprehensive CE library to meet license renewal and state requirements
 - Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
 - Plus much more!
 
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote